Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis-Reference-Cited by-同舟云学术

Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis

Published:2024-07-23 Issue: Volume: Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Weinbergerová Barbora¹^ORCID,Mayer Jiří¹,Kabut Tomáš¹,Sperr Wolfgang R.²³,Števková Jana⁴,Jonášová Anna⁵,Čerňan Martin⁶,Herndlhofer Susanne²,Oravcová Iveta⁷,Šrámek Jiří⁸,Novák Jan⁹,Štěpánová Radka¹⁰,Szotkowski Tomáš⁶,Drgoňa Luboš⁷,Žák Pavel⁴,Valent Peter²³

Affiliation:

1. Department of Internal Medicine – Hematology and Oncology Masaryk University and University Hospital Brno Brno Czech Republic

2. Division of Hematology and Hemostaseology, Department of Internal Medicine I Medical University of Vienna Vienna Austria

3. Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria

4. 4th Department of Internal Medicine‐Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic

5. Medical Department, Hematology Charles University General Hospital Prague Czech Republic

6. Department of Hemato‐Oncology, Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic

7. Department of Oncohematology Comenius University and National Cancer Institute Bratislava Slovakia

8. Department of Haematology and Oncology University Hospital Pilsen Pilsen Czech Republic

9. Department of Haematology, 3rd Faculty of Medicine Charles University and University Hospital Kralovske Vinohrady Prague Czech Republic

10. Faculty of Medicine, Center of Excellence CREATIC Masaryk University Brno Czech Republic

Abstract

SummaryOur observational study analysed fungal infection frequency within cohorts with versus without antifungal prophylaxis (AFP) among newly diagnosed first‐line venetoclax and azacitidine (VEN + AZA)‐treated acute myeloid leukaemias in Czech, Austrian and Slovak haematology centres. Among 186 patients, 85 (46%) received antifungal prophylaxis, while 101 (54%) received no prophylaxis. Fungal infections occurred in 1/85 patients with prophylaxis (1%) and 5/101 patients without prophylaxis (5%) (p = 0.222). No significant difference was recorded between cohorts with and without AFP in terms of death rate (p = 0.296) and overall survival (p = 0.844). In conclusion, most infections were not severe, developing during the first treatment‐cycle and did not affect patients' overall outcome.

Funder

Cellulose and Renewable Materials Division of the American Chemical Society

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19670

Reference12 articles.

1. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

2. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax

3. Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

4. Infections of Venetoclax-Based Chemotherapy in Acute Myeloid Leukemia: Rationale for Proper Antimicrobial Prophylaxis